Lenalidomide and pomalidomide modulate hematopoietic cell expansion and differentiation in the presence of MSC.

ABSTRACT: Cytopenia is a well-documented complication in the treatment of hematological malignancies with lenalidomide and pomalidomide. Although prior studies have highlighted direct effects on hematopoietic cells to explain this adverse effect, the involvement of hematopoietic-supportive stroma remains less understood. This study examined the effects of lenalidomide/pomalidomide on the expansion and differentiation of human CD34⁺ hematopoietic stem/progenitor cells (HSPCs) in vitro, in co-culture with human bone-marrow mesenchymal stromal/stem cells (MSCs). Our findings indicate that lenalidomide/pomalidomide increases the population of immature CD34⁺CD38^- cells while decreasing the number of mature CD34⁺CD38⁺ cells, suggesting a mechanism tha

SUBMITTER: Fujii S 

PROVIDER: S-EPMC11362235 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature